Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
In patients with diabetes and a history of peripheral vascular events, GLP-1 therapies were associated with reduced risk of amputation, major adverse cardiovascular events, cardiovascular death, all-cause mortality, and progression to dialysis compared with other glucose-lowering medications (Hsiao et al., 2026)
Using Leprcre, Ppgcre, and Ppgfl mouse lines, along with Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), we examined roles for Ppg in GLP1NTS and LepRbNTS cells for the control of food intake and energy balance
$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore'] The Glucagon Like Peptide-1 (GLP-1) ELISA quantitates GLP-1 in human serum, plasma, buffered solution, or cell culture medium